1. Home
  2. Stocks
  3. Lupin Share Price
  • Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Lupin Share Price

    Large Cap
    ₹2,224.95
    -45.45 (-2%)
    • Advice
    • Hold
    18 September, 2024 16:45 BSE: 500257 NSE: LUPIN ISIN: INE326A01037

    Start SIP in Lupin

    Start SIP

    Lupin Performance

    Day Range

    • Low 2,213
    • High 2,279
    ₹ 2,224

    52 Week Range

    • Low 1,092
    • High 2,312
    ₹ 2,224
    • Open Price2,274
    • Previous Close2,270
    • Volume503570

    Lupin Chart

    • Over 1 Month + 6.66%
    • Over 3 Month + 38.7%
    • Over 6 Month + 35.93%
    • Over 1 Year + 93.36%

    Lupin Key Statistics

    P/E Ratio 44.8
    PEG Ratio 0.3
    Market Cap Cr
    Price to Book Ratio 7.1
    EPS 50.5
    Dividend 0.4
    Relative Strength Index 68.85
    Money Flow Index 69.4
    MACD Signal 74.96
    Average True Range 47.89

    Lupin F&O

    Lupin Futures Lupin Option Chain

    Lupin Investment Rating

    • Master Rating:

    • Lupin (Nse) has an operating revenue of Rs. 20,797.09 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 12% is healthy, ROE of 13% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 36% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 54 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Lupin Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 4,0843,3324,1163,5603,4962,745
    Operating Expenses Qtr Cr 2,9682,6962,8982,8242,7912,574
    Operating Profit Qtr Cr 1,2007001,217835705262
    Depreciation Qtr Cr 141290145149140146
    Interest Qtr Cr 141311151629
    Tax Qtr Cr 1944416814710023
    Net Profit Qtr Cr 889384916549477119
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 14,77311,350
    Operating Expenses Annual Cr 11,20710,176
    Operating Profit Annual in Cr 3,4591,083
    Depreciation Cr 725548
    Interest Annual Cr 5698
    Tax Annual Cr 459102
    Net Profit Annual Cr 2,326425
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 2,5041,794
    Cash from Investing Activity Annual Cr -1,599-1,269
    Cash from Financing Annual Activity Cr -867-498
    Net Cash Flow Annual Cr 3827
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 20,60318,412
    Fixed Assets Annual Cr 4,5594,949
    Total Non Current Assets Annual Cr 15,63515,113
    Total Current Assets Annual Cr 9,2887,571
    Total Assets Annual Cr 24,92322,684
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 452405
    ROE Annual % 112
    ROCE Annual % 133
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2410
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 5,5144,8955,1974,9394,8144,330
    Operating Expenses Qtr Cr 4,3593,9644,1594,1213,9583,852
    Operating Profit Qtr Cr 1,2419971,038918856578
    Depreciation Qtr Cr 248457257248235264
    Interest Qtr Cr 687174818693
    Tax Qtr Cr 18712911713410516
    Net Profit Qtr Cr 801359613489452236
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 20,13116,715
    Operating Expenses Annual Cr 16,20014,844
    Operating Profit Annual in Cr 3,8111,798
    Depreciation Cr 1,197881
    Interest Annual Cr 312274
    Tax Annual Cr 487269
    Net Profit Annual Cr 1,914430
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 3,6481,897
    Cash from Investing Activity Annual Cr -1,712-1,287
    Cash from Financing Annual Activity Cr -2,184-337
    Net Cash Flow Annual Cr -248273
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 14,29012,465
    Fixed Assets Annual Cr 7,3267,374
    Total Non Current Assets Annual Cr 10,55010,505
    Total Current Assets Annual Cr 13,44812,451
    Total Assets Annual Cr 23,99722,956
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 315276
    ROE Annual % 133
    ROCE Annual % 187
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2011
    Invest in Lupin

    Lupin Technicals

    EMA & SMA

    Current Price
    ₹2,224.95
    -45.45 (-2%)
    pointer
    • Bullish Moving Average
    • ___
    • 11
    • Bearish Moving Average
    • ___
    • 5
    • 20 Day
    • ₹2,198.83
    • 50 Day
    • ₹2,054.73
    • 100 Day
    • ₹1,894.35
    • 200 Day
    • ₹1,684.65
    • 20 Day
    • ₹2,210.73
    • 50 Day
    • ₹2,033.63
    • 100 Day
    • ₹1,828.18
    • 200 Day
    • ₹1,659.07

    Lupin Resistance and Support

    PIVOT
    ₹2,269.15
    Resistance
    First Resistance 2,287.25
    Second Resistance 2,304.10
    Third Resistance 2,322.20
    RSI 68.85
    MFI 69.40
    MACD Single Line 74.96
    MACD 65.47
    Support
    First Support 2,252.30
    Second Support 2,234.20
    Third Supoort 2,217.35

    Lupin Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 963,141 56,045,175 58.19
    Week 1,250,437 80,015,476 63.99
    1 Month 1,335,235 74,452,696 55.76
    6 Month 1,431,572 70,848,492 49.49

    Lupin Result Highlights

    Lupin Synopsis

    NSE-Medical-Generic Drugs

    Lupin Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 14666.50 Cr. and Equity Capital is Rs. 91.14 Cr. for the Year ended 31/03/2024. Lupin Ltd. is a Public Limited Listed company incorporated on 01/03/1983 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1983PLC029442 and registration number is 029442.
    Market Cap 103,561
    Sales 15,338
    Shares in Float 24.18
    No of funds 825
    Yield 0.35
    Book Value 5.02
    U/D Vol ratio 2.6
    LTDebt / Equity
    Alpha 0.23
    Beta 0.51

    Lupin Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 46.98%47.01%47.04%47.06%
    Mutual Funds 16.23%16.82%18.92%16.71%
    Insurance Companies 9.41%9.95%9.7%12.26%
    Foreign Portfolio Investors 19.32%18.29%16.11%14.99%
    Financial Institutions/ Banks 0.15%0.07%0.14%0.14%
    Individual Investors 5.65%5.7%5.87%6.24%
    Others 2.26%2.16%2.22%2.6%

    Lupin Management

    Name Designation
    Mrs. Manju D Gupta Chairman
    Mr. Nilesh D Gupta Managing Director
    Ms. Vinita Gupta Director & CEO
    Mr. Ramesh Swaminathan Executive Director & Global CFO
    Mr. Mark D McDade Independent Director
    Dr. Punita Kumar-Sinha Independent Director
    Mr. Jean-Luc Belingard Independent Director
    Mr. Jeffrey Kindler Independent Director
    Mr. Alfonso Zulueta Independent Director

    Lupin Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Lupin Corporate Action

    Date Purpose Remarks
    2024-08-06 Quarterly Results
    2024-05-06 Audited Results & Final Dividend
    2024-02-07 Quarterly Results
    2023-11-08 Quarterly Results
    2023-08-03 Quarterly Results
    Date Purpose Remarks
    2024-07-16 FINAL Rs.8.00 per share(400%)Final Dividend
    2023-07-14 FINAL Rs.4.00 per share (200%)Final Dividend
    2022-07-15 FINAL Rs.4.00 per share(200%)Final Dividend
    2021-07-28 FINAL Rs.6.50 per share(325%)Final Dividend

    Lupin MF Shareholding

    Name Amount(cr)
    HDFC Balanced Advantage Fund Growth 95,391
    ICICI Prudential Bluechip Fund Growth 64,223
    HDFC Flexi Cap Fund Growth 63,436
    ICICI Prudential Balanced Advantage Fund Growth 61,103
    Kotak Equity Arbitrage Fund Growth 53,423

    About Lupin

    Dr Desh Bandhu Gupta founded in 1968 in Mumbai, Lupin is one of the top pharmaceutical manufacturers. It has 15 manufacturing facilities, 6 API facilities, 7 research facilities and more than 23 global offices. 

    Lupin ranks 6th by sales in India. It ranks #2 in respiratory and #3 in cardiac and anti-diabetes segments. While the market growth in the chronic disease portfolio has been 11% in the last five years, Lupin has been growing at 14% YoY.
     
    Over the last 4 years, it has invested over $1bn in R&D in areas of biosimilars, complex generics, long-acting complex injectables, inhalation and speciality portfolio. 

    Business Verticals

    1. Global Formulations
    2. Active Pharmaceuticals Ingredients (API)
    3. Biotech
    4. Specialty Business
    5. Over The Counter (OTC)
    6. Biosimilars
    7. Generic drugs

    Company History

    Lupin commenced operations in 1968 on Gudi Padwa as a vitamins manufacturer. It is named after the Lupin flower, which can tolerate infertile soils and poor climatic conditions. Its first major order was iron and folic acid tablets for mother and child healthcare programmes backed by the Government of India.

    Today, it develops branded and generic formulations, APIs, and biotechnology products and sells across 100 markets, including the US, Japan, and Mexico. Lupin is one of the world's largest manufacturers of TB drugs. The company has a significant market share across multiple therapy areas such as Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System, Gastro-Intestinal, Anti-Infective, and Non-Steroidal Anti-Inflammatory Drugs. 
     

    Milestones
     

    1968 - Dr Desh Bandhu Gupta started Lupin.

    1972 - Lupin Laboratories Pvt. Ltd. was incorporated.

    1979 - They commissioned the first formulation plant and R&D Centre at Aurangabad.

    1981 - They started the production of Ethambutol.

    1987 - Cephalexin plant at Mandideep and 7 ADCA plants at Ankleshwar went on stream.

    1988 - Commenced Lupin Human Welfare and Research Foundation (LHWRF).

    1989 - Started Lupin Chemicals (Thailand) Ltd. Received U.S. FDA approvals for the Ankleshwar and Mandideep plants.

    1991 - Initiated the production of injectable Cephalosporin at Mandideep.

    1992 - Commenced a sterile fermentation plant for injectable Cephalosporins at Mandideep.

    1993 - Lupin Laboratories Ltd. and Lupin Chemicals Ltd. floated their IPOs.

    1997 - Three facilities received U.S. FDA approvals.

    2000 - Another plant received US FDA approval.

    2001 - Lupin Laboratories Ltd. amalgamated with Lupin Chemicals Ltd. to form Lupin Ltd. and established the Lupin Research Park in Pune. Lupin became the only Asian pharmaceutical company to receive U.S. FDA approvals for its sterile Cephalosporin facility.

    2002 - ORG-Marg rated Rablet as the 2nd best launch of 2002-03; patent filings exceed 100.

    2003 - Received WHO approval for the formulation plant at Aurangabad. Lupin Pharmaceuticals Inc. USA is formed.

    2004 - Started U.S. brands’ business with the launch of Suprax.

    2005 - Commenced its generics business in the U.S. Implemented ESOP.

    2006 - Announced the issue of FCCBs, with a listing on the Singapore Stock Exchange.

    2007 - Acquired Kyowa Pharmaceuticals of Japan; and Rubamin Laboratories of India.

    2008 - Acquired Hormosan Pharma GmbH, Germany. Also acquired stakes in Generic. Health Pty Ltd., Australia and Pharma Dynamics, South Africa.

    2009 - Acquired majority stake in Multi-Care Pharmaceuticals Inc., Philippines.

    2010 - Lupin ranked the 5th largest generic player in the U.S.

    2011 - Began commercial production at the new oral solid dosage facility at Pithampur; acquired I’rom Pharmaceuticals, Japan and of worldwide rights for the Goanna Brand.

    2012 - Lupin enters Nifty 50.

    2014 - Acquired Nanomi BV of the Netherlands and Laboratorios Grin S.A. De C.V., Mexico.

    2015 - Acquired Pharma Dynamics, South Africa, Medquimica Industria, Brazil; Specialty product portfolio of Temmler Pharma GMBH & Co., Germany.

    2016 - Acquired Gavis Pharma, U.S; launched a new plant at Tottori, Japan.

    2017 - Launched Softovac in the OTC segment; acquired Symbiomix Therapeutics, U.S.

    2019 - Divestment of Kyowa Pharmaceutical Industry Co. Ltd in Osaka.

    2020 - Launched Etanercept Biosimilar in EU and gProAir, a key inhalation product.

    Lupin FAQs

    What is Share Price of Lupin ?

    Lupin share price is ₹2,224 As on 18 September, 2024 | 16:31

    What is the Market Cap of Lupin ?

    The Market Cap of Lupin is ₹101488.3 Cr As on 18 September, 2024 | 16:31

    What is the P/E ratio of Lupin ?

    The P/E ratio of Lupin is 44.8 As on 18 September, 2024 | 16:31

    What is the PB ratio of Lupin ?

    The PB ratio of Lupin is 7.1 As on 18 September, 2024 | 16:31

    What were the company's reported sales and net income in 2022?

    For the year ending March 2022, Lupin reported a consolidated sales figure of INR 16,405 crores and a net loss of INR 1,528 crores. Its standalone sales and net loss for the same period stood at INR 11,772 crores and 189 crores respectively.

    What is the future of Lupin Limited's shares?

    Lupin’s future looks slightly bleak. The company has shown a negative net profit growth rate of 2.18% and revenue growth of 3.10% for the past 3 years. However, the company is virtually debt-free.

    How to buy Lupin’s shares?

    You can easily buy and sell the company's shares by creating a Demat account with 5Paisa.
     

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of ₹10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.